TABLE 4.
Longitudinal Tumor Fraction (TFx) Values and Corresponding Clinical Information for All Patients With Diagnostic Aqueous Humor Tumor Fraction Values Greater Than 10% and 2 or More Samples
| Case ID_Eye if Bilateral | Sample Timing | Time From Last Sample (wk) | TFx (%) | Therapeutic Response |
|---|---|---|---|---|
| 33 | DX | — | 97.0 | Baseline examination |
| IVitC 1 | 11 | 94.0 | Progressed | |
| IVitC 2 | 2 | 90.7 | Regressed | |
| IVitC 3 | 4 | 97.4 | Regressed | |
| SE | 3 | 94.0 | Progressed | |
| 47 | DX | — | 22.7 | Baseline examination |
| IVitC 1 | 25 | 6.2 | Progressed | |
| IVitC 2 | 2 | 5.5 | Progressed | |
| IVitC 3 | 2 | 2.0 | Regressed | |
| 51 | DX | — | 41.9 | Baseline examination |
| IAC end | 17 | 5.4 | Regressed | |
| END | 45 | a11.1 | Regressed | |
| 55 | DX | — | 46.4 | Baseline examination |
| IVitC 1 | 8 | 46.8 | Regressed | |
| SE | 4 | 47.6 | Progressed | |
| 66 | DX | — | 87.0 | Baseline examination |
| IVitC 1 | 4 | 99.5 | Progressed | |
| IVitC 2 | 5 | 93.1 | Regressed | |
| IVitC 3 | 4 | 63.4 | Regressed | |
| IVitC 4 | 4 | 24.6 | Progressed | |
| 67 | DX | — | 45.9 | Baseline examination |
| SE | 4 | 3.1 | Progressed | |
| 73 | DX | — | 41.8 | Baseline examination |
| IVitC 1 | 9 | 39.3 | Progressed | |
| IVitC 2 | 3 | 40.4 | Regressed | |
| IVitC 3 | 5 | 46.5 | Regressed | |
| IVitC 4 | 4 | 39.6 | Regressed | |
| IVitC 5/IVC end | 3 | 43.7 | Regressed | |
| IVitC 6a | 4 | 55.6 | Progressed | |
| IVitC 7 | 2 | 6.0 | Progressed | |
| IVitC 8 | 1 | 9.9 | Regressed | |
| IVitC 9 | 2 | 27.0 | Regressed | |
| IVitC 10 | 1 | 8.5 | Regressed | |
| IVitC 11 | 2 | 9.9 | Regressed | |
| IVitC 12 | 2 | 5.7 | Regressed | |
| IViatC 13 | 1 | 5.3 | Regressed | |
| IVitC 14 | 2 | 0.6 | Regressed | |
| IVitC 15 | 2 | 0.0 | Regressed | |
| 74_OD | DX | — | 39.5 | Baseline examination |
| IVC end | 5 | 1.7 | Regressed | |
| REC 1 | 4 | 0.0 | Progressed | |
| END | 9 | 0.0 | Regressed | |
| 74_OS | DX | — | 36.1 | Baseline examination |
| IVC End | 5 | 7.6 | Regressed | |
| 76 | DX | — | 64.2 | Baseline examination |
| IVC End | 4 | 2.3 | Regressed | |
| IVitC 1 | 7 | 5.7 | Progressed | |
| IVitC 2 | 3 | 8.8 | Regressed | |
| IVitC 3 | 4 | 2.7 | Regressed | |
| IVitC 4 | 2 | 0.0 | Regressed | |
| IVitC 5 | 2 | 4.0 | Regressed | |
| 78 | DX | — | 13.6 | Baseline examination |
| IVC end | 4 | 2.4 | Regressed | |
| END | 21 | 3.8 | Regressed | |
| 76 | DX | — | 64.2 | Baseline examination |
| IVC end | 4 | 2.3 | Regressed | |
| IVitC 1 | 7 | 5.7 | Progressed | |
| IVitC 2 | 3 | 8.8 | Regressed | |
| IVitC 3 | 4 | 2.7 | Regressed | |
| IVitC 4 | 2 | 0.0 | Regressed | |
| IVitC 5 | 2 | 4.0 | Regressed | |
| 78 | DX | — | 13.6 | Baseline examination |
| IVC end | 4 | 2.4 | Regressed | |
| END | 21 | 3.8 | Regressed |
DX = diagnostic, END = end of treatment, IAC = intra-arterial chemotherapy, IVC = systemic intravenous chemotherapy, IVitC = intravitreal chemotherapy, REC = retinal recurrence, SE = secondary enucleation, TFx = tumor fraction.
a
Initiation of topoisomerase and melphalan combination intravitreal chemotherapy.